Reuters - GlaxoSmithKline Plc's diabetes drug Avandia should be allowed to stay on the market but with additional warnings, U.S. health advisers recommended on Wednesday, easing a threat of further costly litigation that could have followed a ban.
Source
الذين يشاهدون الموضوع الآن: 1 (0 من الأعضاء و 1 زائر)
ضوابط المشاركة
|
|
||
|
|
|
|
|
|
||
مواقع النشر (المفضلة)